Tubulis Reports the First Patient Dosing with TUB-040 in P-I/IIa Study to Treat Ovarian Cancer and Lung Adenocarcinoma-aa
Shots:
- Tubulis has dosed the first patient in the US with TUB-040 under the P-I/IIa (NAPISTAR 1-01) study for treating Pt-resistant high-grade ovarian cancer (PROC) or r/r lung adenocarcinoma
- The P-I/IIa (NAPISTAR 1-01) trial evaluates the safety of TUB-040 alone with P-I finding the MTD or the identified dose for optimization as well as P-IIa designed for dose optimization and preliminary efficacy across the US, UK, Spain, Belgium & Germany
- TUB-040 is an antibody-drug conjugate that comprises an IgG1 antibody linked with Topoisomerase I inhibitor Exatecan via a cleavable linker system. It targets Napi2b which is highly expressed in ovarian cancer and lung adenocarcinoma
Ref: Tubulis | Image: Tubulis
Related News:- Tubulis Entered into a License Agreement with BMS to Develop ADCs Therapies for the Treatment of Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
